
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZOLINZA | Merck & Co | N-021991 RX | 2006-10-06 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| zolinza | New Drug Application | 2024-11-12 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| t-cell lymphoma cutaneous | — | D016410 | C84.A |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 31 | 30 | 3 | — | 1 | 51 |
| Leukemia | D007938 | — | C95 | 20 | 17 | 1 | — | — | 31 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 18 | 12 | 1 | — | — | 28 |
| Multiple myeloma | D009101 | — | C90.0 | 15 | 10 | 2 | — | — | 23 |
| Non-small-cell lung carcinoma | D002289 | — | — | 17 | 11 | 1 | — | — | 23 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 17 | 9 | 1 | — | — | 22 |
| T-cell lymphoma | D016399 | — | — | 11 | 10 | 1 | — | 1 | 19 |
| Lung neoplasms | D008175 | — | C34.90 | 14 | 9 | 1 | — | 1 | 19 |
| Plasma cell neoplasms | D054219 | — | — | 10 | 8 | 2 | — | — | 17 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 7 | 6 | 1 | — | 1 | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 32 | 4 | — | — | — | 34 |
| Recurrence | D012008 | — | — | 19 | 16 | — | — | — | 32 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 15 | 14 | — | — | — | 24 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 13 | — | — | 3 | 22 |
| Myelodysplastic syndromes | D009190 | — | D46 | 12 | 11 | — | — | — | 20 |
| Myeloid leukemia | D007951 | — | C92 | 13 | 11 | — | — | — | 20 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 13 | 10 | — | — | — | 18 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 7 | 11 | — | — | — | 16 |
| Carcinoma | D002277 | — | C80.0 | 8 | 9 | — | — | — | 15 |
| Follicular lymphoma | D008224 | — | C82 | 8 | 9 | — | — | — | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Germ cell and embryonal neoplasms | D009373 | — | — | 5 | — | — | — | — | 5 |
| Medulloblastoma | D008527 | — | — | 4 | — | — | — | — | 4 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 4 | — | — | — | — | 4 |
| Primitive neuroectodermal tumors | D018242 | — | — | 3 | — | — | — | — | 3 |
| Pinealoma | D010871 | — | — | 3 | — | — | — | — | 3 |
| Plasmacytoma | D010954 | — | C90.3 | 3 | — | — | — | — | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | 1 | 3 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 3 | — | — | — | — | 3 |
| T-cell leukemia | D015458 | — | — | 3 | — | — | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
| Pruritus | D011537 | — | L29 | — | — | — | — | 1 | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | — | — | — | 1 | 1 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 1 | 1 |
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | — | — | 1 | 1 |
| Autism spectrum disorder | D000067877 | — | F84.0 | — | — | — | — | 1 | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | — | — | 1 | 1 |
| Pheochromocytoma | D010673 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Vorinostat |
| INN | vorinostat |
| Description | Vorinostat is a dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a hydroxamic acid and a dicarboxylic acid diamide. It is functionally related to a suberic acid, a hydroxylamine and an aniline. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | O=C(CCCCCCC(=O)Nc1ccccc1)NO |
| PDB | — |
| CAS-ID | 149647-78-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL98 |
| ChEBI ID | 45716 |
| PubChem CID | 5311 |
| DrugBank | DB02546 |
| UNII ID | 58IFB293JI (ChemIDplus, GSRS) |

